Hui Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui Dong has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Wen-Ming Cong
Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
8 shared publications Han Wang
Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China; Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai 200433, China
5 shared publications- Miaoxia He
Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China
4 shared publications Wei Dong
The Department of Pathology, Eastern Hepatobilliary Surgery Hospital, Naval Medical University, 225 Changhai Road, Shanghai, 200438, China
4 shared publicationsWen-Ming Cong
Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China
4 shared publicationsXia Sheng
Department of Pathology, Minhang Hospital, Fudan University, Shanghai 201199, China
4 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Springer Nature in npj Precision Oncology
MAVEN: an automated multimodal framework for predicting VETC and early recurrence in HCC
- 2 October 2026
- Published by Springer Nature in npj Precision Oncology
Open AccessMAVEN: an automated multimodal framework for predicting VETC and early recurrence in HCC
- 9 July 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (4) , 189657
Regulation of tumorigenesis by cellular senescence: Mechanisms and pathways in liver cancer and cholangiocarcinoma
- 9 July 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (4) , 189657
Regulation of tumorigenesis by cellular senescence: Mechanisms and pathways in liver cancer and cholangiocarcinoma
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 163
Prognostic and therapeutic significance of microscopic tumor foci in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study
Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer lacking personalized pathological parameters. Microscopic tumor focus (MTF), a microscopic intrahepatic metastatic pattern, remains poorly characterized, with unclear prognostic and therapeutic relevance in cHCC-CCA. In this study, the detailed significance of MTF in cHCC-CCA was investigated. Methods: A multicenter study included 310 cHCC-CCA patients who underwent curative-intent hepatectomy. MTF was further graded by its number/distribution (MTF 0: absence of MTF; MTF 1: 1–5 proximal MTFs; MTF 2: >5 proximal MTFs/≥1 distal MTFs) and subclassified by its histology (HCC-type MTF; CCA-type MTF; HCC + CCA-type MTF). Results: MTF was detected in 48.1% (149/310) of patients (MTF 1: 43.2%, MTF 2: 4.8%; HCC-type MTF: 17.7%; CCA-type MTF: 20.6%; HCC + CCA type MTF: 9.7%). MTF positivity correlated with poorer recurrence-free survival (RFS) (median time: 0.23 and 0.89 years), early RFS, and overall survival (OS) (median time: 1.53 and 2.95 years, all P0.1 cm improved RFS, early RFS, and OS, while surgical margin had no effect on MTF-negative patients. Age, tumor diameter, microvascular invasion and perineural invasion independently predicted MTF (area under the curve =0.704); MTF histology was an independent prognostic factor for RFS, early RFS, and OS (all Harrell’s concordance index >0.7). Conclusions: This study standardized the definition of MTF and confirmed its prognostic value in cHCC-CCA. MTF stratification based on its number/distribution and histology enables more precise prognostic assessment. The presence of MTF could guide individualized selection of surgical margin.
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 163
Open AccessPrognostic and therapeutic significance of microscopic tumor foci in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study
Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer lacking personalized pathological parameters. Microscopic tumor focus (MTF), a microscopic intrahepatic metastatic pattern, remains poorly characterized, with unclear prognostic and therapeutic relevance in cHCC-CCA. In this study, the detailed significance of MTF in cHCC-CCA was investigated. Methods: A multicenter study included 310 cHCC-CCA patients who underwent curative-intent hepatectomy. MTF was further graded by its number/distribution (MTF 0: absence of MTF; MTF 1: 1–5 proximal MTFs; MTF 2: >5 proximal MTFs/≥1 distal MTFs) and subclassified by its histology (HCC-type MTF; CCA-type MTF; HCC + CCA-type MTF). Results: MTF was detected in 48.1% (149/310) of patients (MTF 1: 43.2%, MTF 2: 4.8%; HCC-type MTF: 17.7%; CCA-type MTF: 20.6%; HCC + CCA type MTF: 9.7%). MTF positivity correlated with poorer recurrence-free survival (RFS) (median time: 0.23 and 0.89 years), early RFS, and overall survival (OS) (median time: 1.53 and 2.95 years, all P0.1 cm improved RFS, early RFS, and OS, while surgical margin had no effect on MTF-negative patients. Age, tumor diameter, microvascular invasion and perineural invasion independently predicted MTF (area under the curve =0.704); MTF histology was an independent prognostic factor for RFS, early RFS, and OS (all Harrell’s concordance index >0.7). Conclusions: This study standardized the definition of MTF and confirmed its prognostic value in cHCC-CCA. MTF stratification based on its number/distribution and histology enables more precise prognostic assessment. The presence of MTF could guide individualized selection of surgical margin.
- Open Access
- 6 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1653534
Immunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection
Introduction: Since the release of the World Health Organization (WHO) Classification of Tumours-Digestive System Tumours in 2019, the pathology of intrahepatic cholangiocarcinoma (iCCA) has entered an era of integrated diagnosis, encompassing gross classification, histological subtyping, as well as drug molecular target screening. Substantial evidence indicates that the histological subtypes of iCCA are significantly associated with the detection frequency of molecular targets relevant to the targeted therapy and immunotherapy. Through rational immunohistochemistry profiling, patients with iCCA can be precisely diagnosed and individually managed.Methods: A thorough literature search was conducted using terms pertinent to the pathological diagnosis, histological subtyping, targeted therapy, and immunotherapy of iCCA. The content related to immunohistochemistry was summarized.Results: In the first part, we summarize the immunohistochemical markers for the histological subtype of iCCA (e.g., large duct type iCCA, small duct type iCCA), with a particular emphasis on their percentage of positive cases, expression location, and association with prognosis. Subsequently, a summary of the immunohistochemical markers for targeted therapy and immunotherapy of iCCA is performed, focusing on the consistency between immunohistochemistry and molecular detection, optimal clone, and prognostic significance.Conclusions: This review summarizes the critical role of immunohistochemistry in the pathological diagnosis of iCCA. It is noted that any diagnosis must be made by integrating comprehensive information. A pathological diagnosis merely based on immunohistochemical results is unreasonable. The development of subtype-specific and drug-targeted antibodies holds promise for refining iCCA precise diagnosis and therapeutic stratification.
- 6 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1653534
Open AccessImmunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection
Introduction: Since the release of the World Health Organization (WHO) Classification of Tumours-Digestive System Tumours in 2019, the pathology of intrahepatic cholangiocarcinoma (iCCA) has entered an era of integrated diagnosis, encompassing gross classification, histological subtyping, as well as drug molecular target screening. Substantial evidence indicates that the histological subtypes of iCCA are significantly associated with the detection frequency of molecular targets relevant to the targeted therapy and immunotherapy. Through rational immunohistochemistry profiling, patients with iCCA can be precisely diagnosed and individually managed.Methods: A thorough literature search was conducted using terms pertinent to the pathological diagnosis, histological subtyping, targeted therapy, and immunotherapy of iCCA. The content related to immunohistochemistry was summarized.Results: In the first part, we summarize the immunohistochemical markers for the histological subtype of iCCA (e.g., large duct type iCCA, small duct type iCCA), with a particular emphasis on their percentage of positive cases, expression location, and association with prognosis. Subsequently, a summary of the immunohistochemical markers for targeted therapy and immunotherapy of iCCA is performed, focusing on the consistency between immunohistochemistry and molecular detection, optimal clone, and prognostic significance.Conclusions: This review summarizes the critical role of immunohistochemistry in the pathological diagnosis of iCCA. It is noted that any diagnosis must be made by integrating comprehensive information. A pathological diagnosis merely based on immunohistochemical results is unreasonable. The development of subtype-specific and drug-targeted antibodies holds promise for refining iCCA precise diagnosis and therapeutic stratification.
- 15 July 2025
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (9) , 102155
Perineural invasion as a prognostic determinant in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study
- 15 July 2025
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 29 (9) , 102155
Perineural invasion as a prognostic determinant in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study
- Open Access
- 1 June 2024
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 13 (3) , 472-493
Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review
Review Article Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review Han Wang, You-Wen Qian, Hui Dong, Wen-Ming Cong
- 1 June 2024
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 13 (3) , 472-493
Open AccessPathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review
Review Article Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review Han Wang, You-Wen Qian, Hui Dong, Wen-Ming Cong
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in Theranostics
- Vol. 14 (9) , 3526-3547
Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma
Background: Immunotherapy has demonstrated its potential to improve the prognosis of patients with hepatocellular carcinoma (HCC); however, patients' responses to immunotherapy vary a lot. A comparative analysis of the tumor microenvironment (TME) in responders and non-responders is expected to unveil the mechanisms responsible for the immunotherapy resistance and provide potential treatment targets.
- 1 January 2024
- Published by Ivyspring International Publisher in Theranostics
- Vol. 14 (9) , 3526-3547
Open AccessSingle cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma
Background: Immunotherapy has demonstrated its potential to improve the prognosis of patients with hepatocellular carcinoma (HCC); however, patients' responses to immunotherapy vary a lot. A comparative analysis of the tumor microenvironment (TME) in responders and non-responders is expected to unveil the mechanisms responsible for the immunotherapy resistance and provide potential treatment targets.
- Open Access
- 1 January 2024
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 11, 191-206
A Grading System of Microvascular Invasion for Patients with Hepatocellular Carcinoma Undergoing Liver Resection with Curative Intent: A Multicenter Study
Background: Microvascular invasion (MVI) is closely correlated with poor clinical outcomes in patients with hepatocellular carcinoma (HCC). A grading system of MVI is needed to assist in the management of HCC patient. Methods: Multicenter data of HCC patients who underwent liver resection with curative intent was analyzed. This grading system was established by detected number and distance from tumor boundary of MVI. Survival outcomes were compared among patients in each group. This system was verified by time-receiver operating characteristic curve, time-area under the curve, calibration curve, and decision curve analyses. Cox regression analysis was performed to study the associated factors of prognosis. Logistic analysis was used to study the predictive factors of MVI. Results: All patients were classified into 4 groups: M0: no MVI; M1: 1~5 proximal MVIs (≤ 1 cm from tumor boundary); M2a: > 5 proximal MVIs (≤ 1 cm from tumor boundary); M2b: ≥ 1 distal MVIs (> 1 cm from tumor boundary). The recurrence-free survival (RFS), overall survival (OS), and early RFS rates among all the individual groups were significantly different. Based on the number of proximal MVI (0~5 vs > 5), patients in the M2b group were further divided into two subgroups which also showed different prognosis. Multiple methods showed this grading system to be significantly better than the MVI two-tiered system in prognostic evaluation. Four multivariate models for RFS, OS, early RFS, late RFS, and a predictive model of MVI were then established and were shown to satisfactorily evaluate prognosis and have a great discriminatory power, respectively. Conclusion: This MVI grading system could precisely evaluate prognosis of HCC patients after liver resection with curative intent and it could be employed in routine pathological reports. The severity of MVI from both adjacent and distant from tumor boundary should be stated. A hypothesis about two occurrence modes of distal MVI was proposed.
- 1 January 2024
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 11, 191-206
Open AccessA Grading System of Microvascular Invasion for Patients with Hepatocellular Carcinoma Undergoing Liver Resection with Curative Intent: A Multicenter Study
Background: Microvascular invasion (MVI) is closely correlated with poor clinical outcomes in patients with hepatocellular carcinoma (HCC). A grading system of MVI is needed to assist in the management of HCC patient. Methods: Multicenter data of HCC patients who underwent liver resection with curative intent was analyzed. This grading system was established by detected number and distance from tumor boundary of MVI. Survival outcomes were compared among patients in each group. This system was verified by time-receiver operating characteristic curve, time-area under the curve, calibration curve, and decision curve analyses. Cox regression analysis was performed to study the associated factors of prognosis. Logistic analysis was used to study the predictive factors of MVI. Results: All patients were classified into 4 groups: M0: no MVI; M1: 1~5 proximal MVIs (≤ 1 cm from tumor boundary); M2a: > 5 proximal MVIs (≤ 1 cm from tumor boundary); M2b: ≥ 1 distal MVIs (> 1 cm from tumor boundary). The recurrence-free survival (RFS), overall survival (OS), and early RFS rates among all the individual groups were significantly different. Based on the number of proximal MVI (0~5 vs > 5), patients in the M2b group were further divided into two subgroups which also showed different prognosis. Multiple methods showed this grading system to be significantly better than the MVI two-tiered system in prognostic evaluation. Four multivariate models for RFS, OS, early RFS, late RFS, and a predictive model of MVI were then established and were shown to satisfactorily evaluate prognosis and have a great discriminatory power, respectively. Conclusion: This MVI grading system could precisely evaluate prognosis of HCC patients after liver resection with curative intent and it could be employed in routine pathological reports. The severity of MVI from both adjacent and distant from tumor boundary should be stated. A hypothesis about two occurrence modes of distal MVI was proposed.
- 28 November 2023
- Published by Elsevier in Cancer Letters
- Vol. 581, 216513
Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma
- 28 November 2023
- Published by Elsevier in Cancer Letters
- Vol. 581, 216513
Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma